Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.56 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.56 |
| ▸ | ABAT | P80404 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 2/20 | 0.51 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28990849 | 0.83 | CNR2 (0.64) | ALDH1A1HPGDNQO2RELAPELI1 | |
| SCHEMBL3920869 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CYP2A6TRIM24TRIM33HPGD | |
| SCHEMBL29541984 | 0.81 | KMT2A (0.61) | ALDH1A1HPGDTDP1RELAKDM4E | |
| SCHEMBL3925842 | 0.81 | ALDH1A1 (0.56) | ALDH1A1CYP2A6TDP1RELANFE2L2 | |
| SCHEMBL3921828 | 0.79 | ALDH1A1 (0.55) | ALDH1A1CYP2A6TRIM24TRIM33HPGD | |
| SCHEMBL10579363 | 0.78 | ESR2 (0.60) | RELAKDM4ERAB9AGAAGFER | |
| SCHEMBL15329599 | 0.78 | KDM4E (0.52) | ALDH1A1TRIM24TRIM33HPGDALDH5A1 | |
| SCHEMBL31194720 | 0.78 | PELI1 (0.62) | ALDH1A1CYP2A6TRIM24TRIM33HPGD | |
| SCHEMBL9763217 | 0.78 | PELI1 (0.62) | ALDH1A1CYP2A6TRIM24TRIM33HPGD | |
| SCHEMBL11078733 | 0.78 | ESR2 (0.61) | ALDH1A1HPGDKDM4ERAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | ALDH1A1 4611/4885CYP2A6 3339/4885TRIM24 2772/4885 |
| US-20070142381-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | ALDH1A1 4712/4885CYP2A6 3419/4885TRIM24 3066/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | ALDH1A1 4417/4885CYP2A6 2842/4885TRIM24 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.